Explore Jobs
Find Specific Jobs
Explore Careers
Explore Professions
Best Companies
Explore Companies
MaxCyte revenue
MaxCyte's revenue is $44.3 million.
What is MaxCyte's revenue?
- MaxCyte's revenue growth from 2020 to 2022 is 69.14%.
- MaxCyte has 65 employees, and the revenue per employee ratio is $680,946.
- MaxCyte's peak quarterly revenue was $12.4M in 2022(q4).
- MaxCyte peak revenue was $44.3M in 2022.
- MaxCyte annual revenue for 2021 was 33.9M, 29.52% growth from 2020.
- MaxCyte annual revenue for 2022 was 44.3M, 30.59% growth from 2021.
On This Page
Automate your job search!
Let us apply for jobs for you!
Automate your job search!
Let us apply for jobs for you!
MaxCyte Jobs
MaxCyte historical revenue
MaxCyte's peak revenue was $44.3M in 2022. The peak quarterly revenue was $12.4M in 2022(q4).
MaxCyte's revenue increased from $26.2m in 2020 to $44.3M currently. That's a 69.14% change in annual revenue.
MaxCyte annual revenue
MaxCyte annual revenue over time
Fiscal Year / Year  | MaxCyte Revenue |
|---|---|
| 2020 | $26.2M |
| 2021 | $33.9M |
| 2022 | $44.3M |
MaxCyte quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
MaxCyte quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2021 | - | $7.1M | $10.1M | $10.2M |
| 2022 | $11.6M | $9.6M | $10.6M | $12.4M |
| 2023 | $8.6M | $9.0M | $8.0M | - |
MaxCyte Jobs Nearby
Do you work at MaxCyte?
Is MaxCyte transparent about its revenue structure?
MaxCyte Financing
MaxCyte received early financing of $1.8M on 2002-12-18.
| Series | Round Size | Date |
|---|---|---|
| Series A | $1.8M | 12/2002 |
| Series B | $10.7M | 03/2004 |
| Series Unknown | $3.4M | 04/2005 |
| Series Unknown | $8.2M | 09/2006 |
| Series Unknown | $1.1M | 10/2007 |
| Series Unknown | $2.1M | 10/2008 |
| Series Unknown | $1.5M | 08/2009 |
| Series Unknown | $1.7M | 12/2014 |
| Post Ipo Equity | $760K | 09/2016 |
MaxCyte Investors
| Investors | Security Type |
|---|---|
| Intersouth Partners | Series B |
| Tall Oaks Capital Partners | Series B |
| Harbert Venture Partners LLC | Series B |
MaxCyte competitors
MaxCyte's top competitor, Poseida Therapeutics, earned an annual revenue of $130.5M.
MaxCyte's smallest competitor is U.S. Stem Cell with revenue of $277.1K last year.
| Company Name | Average Salary | Revenue | Employee Size | Job Openings |
|---|---|---|---|---|
| BioTime | - | $3.4M | 101 | - |
| U.S. Stem Cell | - | $277,087 | 5 | - |
| Takara Bio Usa, Inc. | - | $95.6M | 175 | - |
| Minerva Biotechnologies | - | $2.4M | 24 | - |
| Cellerant Therapeutics | - | $3.8M | 7 | - |
| Poseida Therapeutics | - | $130.5M | 200 | - |
| AVROBIO | - | $1.2M | 49 | - |
| Taiga Biotech | - | $1.2M | 15 | - |
| Health Discovery | - | $1.6M | 5 | - |
Search for jobs
Related Company Revenues
Working At Related Companies
Related Company Jobs
Most In Demand Jobs
Zippia gives an in-depth look into the details of MaxCyte, including salaries, political affiliations, employee data, and more, in order to inform job seekers about MaxCyte. The employee data is based on information from people who have self-reported their past or current employments at MaxCyte. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by MaxCyte. The data presented on this page does not represent the view of MaxCyte and its employees or that of Zippia.
MaxCyte may also be known as or be related to MAXCYTE INC., MAXCYTE, INC., MaxCyte, MaxCyte Inc, MaxCyte Inc., MaxCyte, Inc. and Maxcyte, Inc.